

2nd ECHA Biocide Stakeholder day

Union Authorisation

Analysis of Benefits and Risks – Industry Perspective

Ludger Grunwald

Regulatory Affairs EMEA

September 2014



ECOLAB[®]



With sales of \$13 billion and more than 45,000 employees, Ecolab is the global leader in water, hygiene and energy technologies and services. Ecolab delivers comprehensive programs and services to the food, energy, healthcare, industrial and hospitality markets in more than 170 countries.



Agenda

- ▲ Introduction
- ▲ Objectives
- ▲ Benefits and Expectations
- ▲ Risks and Challenges
- ▲ Possible Next Steps
- ▲ Summary



Agenda

- ▲ Introduction
- ▲ **Objectives**
- ▲ Benefits and Expectations
- ▲ Risks and Challenges
- ▲ Possible Next Steps
- ▲ Summary



Objectives & Criteria

Union Authorization (UA)

- ▲ Harmonisation
- ▲ To facilitate access to the entire EU market
- ▲ One Authorisation valid across EU*
- ▲ Products with similar conditions of use
- ▲ Not open to substances fulfilling the exclusion criteria, rodenticides or antifouling products (Article 42(1))
- ▲ Progressive phase-in period for workability until January 2020

Timeline

Union Authorization

- ▲ Pre-defined phase-in periods according to Article 42(1):
Dossier Submission possible before!

1. Step

**1 September
2013:**

**PT 1, 3, 4, 5,
18 and 19**

**Or a BP
containing
new active
substances**

2. Step

**1 January
2017:**

**PT 2, 6 and
13**

3. Step

**1 January
2020:**

**All remaining
PTs (beside
those
excluded)**


Agenda

- ▲ Introduction
- ▲ Objectives
- ▲ **Benefits and Expectations**
- ▲ Risks and Challenges
- ▲ Possible Next Steps
- ▲ Summary



Benefits and Expectations

Union Authorization



Benefits and Expectations:

Union Authorization

- ▲ One authorization valid across the EU market = easy market access
- ▲ ECHA driven process with clear deadlines = predictability
- ▲ Avoiding unnecessary testing due to optimized data requirements = lower investment in data

While:

- ▲ Effective products while ensuring a high level of protection for human health and the environment
- ▲ Reduced uncertainty related to data protection and waiving
- ▲ Increasing competitiveness and innovation (biocidal family)

Agenda

- ▲ Introduction
- ▲ Objectives
- ▲ Benefit and Expectations
- ▲ **Risks and Challenges**
- ▲ Possible Next Steps
- ▲ Summary



Challenges and Risk:

Union Authorisation

- ▲ First risk/challenge: Union Authorisation is a new process,
 - how do you pick the right authorisation strategy for your company
 - how do you justify it financially

- ▲ Risks related to the next steps:
 - Finding a eCA to support your application
 - Dossier Preparation and addressing technical questions (e.g. Creating the right Biocide product family)

- ▲ While:
 - Ensuring compliance to Art 95
 - Ensuring technical equivalence
 - Time lines and process constraints

Challenges and Risk:

Union Authorisation – Find a eCA

Evaluating Competent Authority (eCA)

Article 43 and 44

- ▲ Capacities
- ▲ Experience & Reputation
- ▲ Working methods
- ▲ Pragmatic
- ▲ Total fees
- ▲ Communication - language

Challenges and Risk:

Union Authorisation – New Process and Timelines

Union Authorisation time lines

Article 42, 43, 44

- ▲ Role of ECHA Dossier Manager ?
- ▲ How to communicate?
- ▲ Helpdesk in practice?
- ▲ New Requirements
 - Pre-submission form
 - SPC's
 - Active Dossier (Annex II)
 - Product Dossier (Annex III)
 - Confirmation “similar condition of use”
 - Confirmation of an eCA

Challenges and Risk:

Union Authorization – Fees

Union Authorization fees

Fee Regulation

- ▲ UA Fees (80k€ / 150k€)
- ▲ Evaluation fees
- ▲ Annual fees UA
- ▲ Annual fees MS (?)
- ▲ Technical Equivalence fees (depends on AS source)
- ▲ Comparative assessment fees (in specific cases)

Challenges and Risk:

Union Authorisation – Authorisation strategy

Authorisation Strategy

MR: Article 32, 33, 34

UA: Article 42, 43, 44

- ▲ UA vs MR or both?
- ▲ Simplified procedure possible – new Annex I?
- ▲ Same Products Authorisation – pick up list?
- ▲ Supplier product / active data (LoA)

Challenges and Risk:

Union Authorisation – Article 95

Approved Suppliers List

Article 95

- ▲ Product Supplier?
- ▲ Substance Supplier?
- ▲ Participant ?
- ▲ Every Legal Entity?
- ▲ *In-situ* ?



Guidance

Challenges and Risk:

Union Authorization – Technical Equivalence

Technical Equivalence

Article 54

- ▲ Responsibility to show TE with formulator but active supplier owns data
- ▲ Status of Participant always enough for TE?
- ▲ Alternative dossiers submission available?
- ▲ Understand data requirements

Challenges and Risk:

Union Authorization – Technical Questions

Technical Questions

Guidance documents

- ▲ Product working acc. to new efficacy guidance?
- ▲ Avoid unnecessary data generation (e.g. waiver of Phy.Chem. endpoints in biocidal families)
- ▲ Risk Assessments
 - Dietary Risk Assessments
- ▲ IUCLID prepared for biocidal family

Agenda

- ▲ Introduction
- ▲ Objectives
- ▲ Benefits and Expectations
- ▲ Risks and Challenges
- ▲ **Possible Next Steps**
- ▲ Summary



Possible Next Steps


▲ Steps for Industry

- Confirm your product portfolio
- Decide on authorisation strategy
- Contribute actively to different guidance development

▲ Regulators

- Build guidance according to the new definition of a Biocide Product Family (including practical examples to understand the possible limitations of the concept)
- Need to finalise guidance on Article 95 and efficacy
- Acceptance of (high) number of SPC's to make it workable for all

Summary



BENEFITS

- Possibility of Union Authorisation
- ECHA involvement & clear deadlines
- Biocidal Product Family



RISKS

- High authorisation costs
- New and highly complex process
- Remaining uncertainties, lack of guidance



QUESTIONS AND ANSWERS

Dr. Ludger Grunwald

REGULATORY AFFAIRS EUROPE, MIDDLE EAST & AFRICA

ECOLAB DEUTSCHLAND GMBH Ecolab-Allee 1, D-40789 Monheim am Rhein, ludger.grunwald@ecolab.com